Failure of buserelin-induced medical castration to control pulmonary lymphangiomyomatosis in two patients.
Two women, aged 44 and 29 years, respectively, were admitted to the hospital in early 1987 for recurrent pneumothorax, dyspnea and a diffuse reticulonodular pattern evidenced on the chest x-ray film. Lung biopsy confirmed LAM in both patients. Both were treated sequentially with medroxyprogesterone and a LHRH agonist (buserelin) to achieve reversible medical castration. Neither subjective nor objective improvement was noted after 13 and 5 months, respectively, of buserelin therapy (900 micrograms/day, nasal spray) despite an effective suppression of the pituitary-gonadal axis. Medroxyprogesterone also was ineffective. Buserelin thus failed to control pulmonary LAM in these two patients, in spite of effective medical castration.
Radermecker
M
M
Department of Respiratory Medicine, CHU, University of Liège, Belgium.
Broux
R
R
Corhay
J L
JL
Limet
R
R
Radermecker
M
M
D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002064:Buserelin / Q000008:administration & dosage*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000150:complications / Q000188:drug therapy*; D008203:Lymphangiomyoma / Q000150:complications / Q000188:drug therapy*; D008525:Medroxyprogesterone / Q000008:administration & dosage / Q000031:analogs & derivatives; D017258:Medroxyprogesterone Acetate; D010053:Ovary / Q000187:drug effects*; D011030:Pneumothorax / Q000209:etiology; D012008:Recurrence; D013629:Tamoxifen / Q000008:administration & dosage
D000970:Antineoplastic Agents; D013629:Tamoxifen; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone; D002064:Buserelin